Clinical Trials · NCT04931342
A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors
- Phase
- Phase 2
- Recruitment status
- Active Not Recruiting
- Sponsor
- Hoffmann-La Roche
- Enrollment
- 176
- Start date
- Oct 2021
- Locations
- 41 sites, 13 countries
- Primary endpoint
- Confirmed Objective Response Rate (ORR)